Source link : https://www.newshealth.biz/health-news/eltrombopag-improves-outcomes-in-kids-with-newly-diagnosed-itp/
SAN DIEGO — Treatment with eltrombopag (Promacta) for pediatric patients with newly diagnosed immune thrombocytopenia (ITP) led to a significantly higher rate of durable platelet response compared with standard first-line therapies, an interim analysis of a phase III trial showed. Of the initial 108 treated children, a significantly higher proportion of those randomized to receive […]
Author : News Health
Publish date : 2024-12-07 15:00:00
Copyright for syndicated content belongs to the linked Source.